These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 19909586)

  • 81. Triggering of ovulation in human menopausal gonadotrophin-stimulated cycles: comparison between intravenously administered gonadotrophin-releasing hormone (100 and 500 micrograms), GnRH agonist (buserelin, 500 micrograms) and human chorionic gonadotrophin (10,000 IU).
    Gerris J; De Vits A; Joostens M; Van Royen E
    Hum Reprod; 1995 Jan; 10(1):56-62. PubMed ID: 7745071
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Impact of final oocyte maturation using gonadotropin-releasing hormone agonist triggering and different luteal support protocols on endometrial gene expression.
    Bermejo A; Cerrillo M; Ruiz-Alonso M; Blesa D; Simón C; Pellicer A; Garcia-Velasco JA
    Fertil Steril; 2014 Jan; 101(1):138-146.e3. PubMed ID: 24182413
    [TBL] [Abstract][Full Text] [Related]  

  • 83. A randomized controlled trial of increasing recombinant follicle-stimulating hormone after initiating a gonadotropin-releasing hormone antagonist for in vitro fertilization-embryo transfer.
    Propst AM; Bates GW; Robinson RD; Arthur NJ; Martin JE; Neal GS
    Fertil Steril; 2006 Jul; 86(1):58-63. PubMed ID: 16753156
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Absence of luteal phase defect and spontaneous pregnancy in IVF patients despite GnRH-agonist trigger and "freeze all policy" without luteal phase support: a report of four cases.
    Gurbuz AS; Deveer R; Ozcimen N; Ozcimen EE; Lawrenz B; Banker M; Garcia-Velasco JA; Fatemi HM
    Gynecol Endocrinol; 2016; 32(1):18-20. PubMed ID: 26487486
    [TBL] [Abstract][Full Text] [Related]  

  • 85. The addition of single dose GnRH agonist to luteal phase support in artificial cycle frozen embryo transfer: a randomized clinical trial.
    Ye H; Luo X; Pei L; Li F; Li C; Chen Y; Zhang X; Huang G
    Gynecol Endocrinol; 2019 Jul; 35(7):618-622. PubMed ID: 30700175
    [TBL] [Abstract][Full Text] [Related]  

  • 86. A randomized prospective trial comparing gonadotropin-releasing hormone (GnRH) antagonist/recombinant follicle-stimulating hormone (rFSH) versus GnRH-agonist/rFSH in women pretreated with oral contraceptives before in vitro fertilization.
    Barmat LI; Chantilis SJ; Hurst BS; Dickey RP
    Fertil Steril; 2005 Feb; 83(2):321-30. PubMed ID: 15705369
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Similar endometrial development in oocyte donors treated with either high- or standard-dose GnRH antagonist compared to treatment with a GnRH agonist or in natural cycles.
    Simon C; Oberyé J; Bellver J; Vidal C; Bosch E; Horcajadas JA; Murphy C; Adams S; Riesewijk A; Mannaerts B; Pellicer A
    Hum Reprod; 2005 Dec; 20(12):3318-27. PubMed ID: 16085660
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Gonadotropin-releasing hormone agonist versus human chorionic gonadotropin as a trigger of ovulation in polycystic ovarian disease gonadotropin hyperstimulated cycles.
    Lanzone A; Fulghesu AM; Villa P; Guida C; Guido M; Nicoletti MC; Caruso A; Mancuso S
    Fertil Steril; 1994 Jul; 62(1):35-41. PubMed ID: 8005301
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Rescue of corpus luteum function with peri-ovulatory HCG supplementation in IVF/ICSI GnRH antagonist cycles in which ovulation was triggered with a GnRH agonist: a pilot study.
    Humaidan P; Bungum L; Bungum M; Yding Andersen C
    Reprod Biomed Online; 2006 Aug; 13(2):173-8. PubMed ID: 16895629
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Increased live birth rates with GnRH agonist addition for luteal support in ICSI/IVF cycles: a systematic review and meta-analysis.
    Kyrou D; Kolibianakis EM; Fatemi HM; Tarlatzi TB; Devroey P; Tarlatzis BC
    Hum Reprod Update; 2011; 17(6):734-40. PubMed ID: 21733980
    [TBL] [Abstract][Full Text] [Related]  

  • 91. GnRH antagonists in ovarian stimulation for IVF.
    Tarlatzis BC; Fauser BC; Kolibianakis EM; Diedrich K; Rombauts L; Devroey P
    Hum Reprod Update; 2006; 12(4):333-40. PubMed ID: 16567347
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Gonadotropin-releasing hormone agonist versus HCG for oocyte triggering in antagonist assisted reproductive technology cycles.
    Youssef MA; Van der Veen F; Al-Inany HG; Griesinger G; Mochtar MH; van Wely M
    Cochrane Database Syst Rev; 2010 Nov; (11):CD008046. PubMed ID: 21069701
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Factors that predict the probability of a successful clinical outcome after induction of oocyte maturation with a gonadotropin-releasing hormone agonist.
    Kummer N; Benadiva C; Feinn R; Mann J; Nulsen J; Engmann L
    Fertil Steril; 2011 Jul; 96(1):63-8. PubMed ID: 21565337
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Comparison of a gonadotropin-releasing hormone (GnRH) antagonist and GnRH agonist flare-up regimen in poor responders undergoing ovarian stimulation.
    Malmusi S; La Marca A; Giulini S; Xella S; Tagliasacchi D; Marsella T; Volpe A
    Fertil Steril; 2005 Aug; 84(2):402-6. PubMed ID: 16084881
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Low-dose GnRH antagonist protocol is as effective as the long GnRH agonist protocol in unselected patients undergoing in vitro fertilization and embryo transfer.
    Huang SY; Huang HY; Yu HT; Wang HS; Chen CK; Lee CL; Soong YK
    Taiwan J Obstet Gynecol; 2011 Dec; 50(4):432-5. PubMed ID: 22212313
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Contribution to More Patient-Friendly ART Treatment: Efficacy of Continuous Low-Dose GnRH Agonist as the Only Luteal Support-Results of a Prospective, Randomized, Comparative Study.
    Pirard C; Loumaye E; Laurent P; Wyns C
    Int J Endocrinol; 2015; 2015():727569. PubMed ID: 25945092
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Effect of luteal-phase GnRH agonist on frozen-thawed embryo transfer during artificial cycles: a randomised clinical pilot study.
    Liu Y; Huang K; Chen C; Wen L; Lei M; Guo Y; Tang B
    Front Endocrinol (Lausanne); 2023; 14():1098576. PubMed ID: 37361538
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Single-administered GnRH agonist as luteal phase support in insemination cycles: a randomized controlled trial.
    Leppänen R; Tinkanen H; Huhtala H; Ahinko K
    Gynecol Endocrinol; 2022 May; 38(5):438-442. PubMed ID: 35323085
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Effects of multiple doses of gonadotropin-releasing hormone agonist on the luteal-phase support in assisted reproductive cycles: A clinical trial study.
    Eftekhar M; Mirzaei M; Mangoli E; Mehrolhasani Y
    Int J Reprod Biomed; 2021 Jul; 19(7):645-652. PubMed ID: 34458673
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Clinical pregnancy following GnRH agonist administration in the luteal phase of fresh or frozen assisted reproductive technology (ART) cycles: Systematic review and meta-analysis.
    Chau LTM; Tu DK; Lehert P; Dung DV; Thanh LQ; Tuan VM
    Eur J Obstet Gynecol Reprod Biol X; 2019 Jul; 3():100046. PubMed ID: 31403130
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.